Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Jennifer Grandis, MD

    TitleAmerican Cancer Society Professor
    SchoolUCSF School of Medicine
    DepartmentOtolaryngology
    Address3333 Calif. St,Laurel Heights
    San Francisco CA 94118
    Phone415-514-8060
    vCardDownload vCard
      Other Positions
      TitleAssociate Vice Chancellor, Clinical and Translational Research

      TitleDirector, Clinical and Translational Science Institute

      TitleProfessor, Otolaryngology – Head and Neck Surgery


      Collapse Biography 
      Collapse Education and Training
      Swarthmore CollegeBABiology1982
      Swarthmore CollegeBAArt History1982
      University of PittsburghM.D.School of Medicine1987
      University of PittsburghResidencySchool of Medicine, Surgery1988
      University of PittsburghResearch FellowshipSchool of Medicine, Infections Disease1992
      University of Pittsburgh ResidencySchool of Medicine, Otolaryngology1993
      Collapse Awards and Honors
      University of Pittsburgh, School of Medicine1987Kenneth H. Hinderer Award in Otolaryngology
      University of Pittsburgh, School of Medicine1987Leo H. Criep, Award in Medicine,
      University of Pittsburgh1986Alpha Omega Alpha
      Swarthmore College1982Oak Leaf Award
      American Society for Clinical Investigation2002Elected Member
      University of Pittsburgh Cancer Institute2003Scientific Leadership Award
      Pittsburgh Magazine2005 - 2014Top Doctor
      American Cancer Society2008 - presAmerican Cancer Society Clinical Research Professorship
      University of Pittsburgh2009Chancellor’s Distinguished Research Award
      MD Anderson Cancer Center2009Waun Ki Hong Visiting Professorship
      University of Pittsburgh School of Medicine2010Philip Hench Distinguished Alumnus Award
      Association of American Physicians2010Elected Member
      University of Pittsburgh2011Provost’s Award for Excellence in Mentoring
      The Ochsner Clinic Foundation2012Alton Oschner Award Relating Smoking and Disease
      Institute of Medicine (IOM) of The National Academies2012Elected Member
      University of Pittsburgh School of Medicine2012Distinguished Professor of Otolaryngology
      University of Pittsburgh and Carnegie Mellon University2014William E. Brown Outstanding MSTP Mentor Award, Medical Scientist Training Program
      2015Peggy Wheelock Award for Excellence in Research, Mentoring, and Promotion of Women in Science

      Collapse Overview 
      Collapse Overview
      Jennifer R. Grandis, MD, is a Professor in the Department of Otolaryngology – Head and Neck Surgery (OHNS), and she is the Associate Vice Chancellor—Clinical and Translational Research (AVC-CTR) at the University of California, San Francisco. She received her medical degree from the University of Pittsburgh School of Medicine, Pennsylvania, and she completed her internship from the same institution. Dr. Grandis completed both a residency and an Infectious Disease fellowship from the University of Pittsburgh School of Medicine, Pennsylvania. Prior to joining UCSF, Dr. Grandis was the UPMC Endowed Chair in Head and Neck Cancer Surgical Research and Distinguished Professor of Otolaryngology and Pharmacology and Chemical Biology at the University of Pittsburgh. She led the Head and Neck Cancer Program and was the Vice Chair for Research in the Department of Otolaryngology.

      Dr. Grandis’s research focuses on the signal transduction in head and neck squamous cell carcinoma (HNSCC) development and progression with the ultimate goal of targeting key pathways for therapeutic benefit. By taking key findings from the clinic and investigating mechanisms in a series of preclinical models, as well as developing novel therapeutic approaches in the laboratory and carrying out innovative clinical trials that employ these treatment strategies.

      Dr. Grandis is an American Cancer Society Clinical Research Professor, and a member of the American Society for Clinical Investigation, the American Association of Physicians and the Institute of Medicine of the National Academies. She has published over 260 peer-reviewed articles. She has also contributed to more than 50 review articles and book chapters.

      Research:
      Dr. Grandis's is dedicated to increasing our understanding of the genetic and epigenetic alterations in the upper aerodigestive tract mucosa, which mediate head and neck squamous cell carcinoma (HNSCC) progression. The overall goal is to identify predictive biomarkers, which can serve to select patients for therapies, including molecular targeting approaches. Translational resources developed to support projects include a large collection of patient-derived xenografts (PDXs) and tissue microarrays of over 500 human HNSCCs linked to a professionally curated clinical and pathologic database that includes information on treatment and survival. To date, the have examined the role of the epidermal growth factor receptor (EGFR), it’s ligands coordinate activation of STAT3 (signal transducer and activator of transcription) in head and neck carcinogenesis. Cumulative evidence from her laboratory suggests that TGF-?lpha/EGFR autocrine signaling leading to STAT3 activation is as early event in head and neck carcinogenesis. Strategies aimed at blocking the ligand, receptor or signaling protein demonstrated anti-tumor efficacy in preclinical models. Based on these promising results, they completed a Phase I clinical trial to investigate the toxicity and biologic effects of EGFR antisense gene therapy and a Phase II study was recently closed to accrual. They have developed STAT3 targeting strategies using a decoy oligonucleotide approach and early phase clinical testing demonstrated feasibility without toxicity. Ongoing studies are aimed at identifying the targetable genetic alterations in these cancers with the goal of designing precision medicine approaches. Emerging targets include activating mutations of the PI3K signaling pathway, primarily in HNSCC linked to HPV infection and mutation or promoter hypermethylation of selected PTPRs, which lead to STAT3 activation.

      Specialty:
      General Otolaryngology

      Expertise:
      Clinical and translational research

      Professional Interests:
      Head and neck cancer, signal transduction, precision medicine, experimental therapeutics, preclinical cancer models, receptor crosstalk

      Education and Training:
      • Medical School: University of Pittsburgh School of Medicine, Pittsburgh, PA
      • Internship: University of Pittsburgh School of Medicine, Pittsburgh, PA
      • Residency: University of Pittsburgh School of Medicine, Pittsburgh, PA
      • Fellowship: University of Pittsburgh School of Medicine, Pittsburgh, PA – Infectious Disease


      Collapse ORNG Applications 
      Collapse Featured Publications
      Collapse Websites
      Collapse In The News
      Collapse NIH Awarded Grants
      Collapse Twitter

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016 Apr 1; 126(4):1606. PMID: 27035818.
        View in: PubMed
      2. Grandis J. HER2 and HER3 in HPV+ and HPV- HNSCC-Response. Clin Cancer Res. 2016 Apr 1; 22(7):1826. PMID: 27037255.
        View in: PubMed
      3. Bauman JE, Grandis J. Oral Cancer Chemoprevention-The End of EPOC, the Beginning of an Epoch of Molecular Selection. JAMA Oncol. 2016 Feb 1; 2(2):178-9. PMID: 26540592.
        View in: PubMed
      4. Prabhu AV, Grandis J, Branstetter BF. A Young Man With Chronic Discharge From the Skin of the Lateral Neck. JAMA Otolaryngol Head Neck Surg. 2016 Jan 1; 142(1):99-100. PMID: 26720864.
        View in: PubMed
      5. Geiger JL, Grandis JR, Bauman JE. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May; 56:84-92. PMID: 26733183.
        View in: PubMed
      6. Li H, Wheeler S, Park Y, Ju Z, Thomas SM, Fichera M, Egloff AM, Lui VW, Duvvuri U, Bauman JE, Mills GB, Grandis JR. Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. Mol Cancer Res. 2016 Mar; 14(3):278-86. PMID: 26685214.
        View in: PubMed
      7. Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Res. 2016 Jan 15; 76(2):440-52. PMID: 26676751.
        View in: PubMed
      8. Khan Z, Epstein JB, Marur S, Gillespie MB, Feldman L, Tsai HL, Zhang Z, Wang H, Sciubba J, Ferris R, Grandis JR, Gibson M, Koch W, Tufano R, Westra W, Tsottles N, Ozawa H, Chung C, Califano JA. Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. Oral Oncol. 2016 Feb; 53:60-6. PMID: 26686755.
        View in: PubMed
      9. Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016 Jan 4; 126(1):169-80. PMID: 26619122.
        View in: PubMed
      10. Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC. PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. J Clin Invest. 2015 Dec 1; 125(12):4529-43. PMID: 26571401.
        View in: PubMed
      11. Chapman BV, Wald AI, Akhtar P, Munko AC, Xu J, Gibson SP, Grandis JR, Ferris RL, Khan SA. MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. BMC Cancer. 2015; 15:861. PMID: 26545583.
        View in: PubMed
      12. Kopechek JA, Carson AR, McTiernan CF, Chen X, Hasjim B, Lavery L, Sen M, Grandis JR, Villanueva FS. Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth. Theranostics. 2015; 5(12):1378-87. PMID: 26681983.
        View in: PubMed
      13. Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Wilson GM, Resnick LO, LaPorte MG, Wipf P, Huryn DM, Grandis JR. HCS Campaign to Identify Selective Inhibitors of IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Assay Drug Dev Technol. 2015 Sep; 13(7):356-76. PMID: 26317883.
        View in: PubMed
      14. Maxwell JH, Grandis JR, Ferris RL. HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. Annu Rev Med. 2016 Jan 14; 67:91-101. PMID: 26332002.
        View in: PubMed
      15. Peyser ND, Du Y, Li H, Lui V, Xiao X, Chan TA, Grandis JR. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. PLoS One. 2015; 10(8):e0135750. PMID: 26267899.
        View in: PubMed
      16. Pollock NI, Wang L, Wallweber G, Gooding WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, Zeng Y, Grandis JR. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Clin Cancer Res. 2015 Oct 15; 21(20):4597-606. PMID: 26138066.
        View in: PubMed
      17. Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene. 2016 Mar 3; 35(9):1163-9. PMID: 25982282.
        View in: PubMed
      18. Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May 1; 1(2):238-44. PMID: 26181029.
        View in: PubMed
      19. Wen Y, Grandis JR. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2015 Jun; 20(2):313-29. PMID: 25826749.
        View in: PubMed
      20. Sen M, Pollock NI, Black J, DeGrave KA, Wheeler S, Freilino ML, Joyce S, Lui VW, Zeng Y, Chiosea SI, Grandis JR. JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. Neoplasia. 2015 Mar; 17(3):256-64. PMID: 25810010.
        View in: PubMed
      21. Wheeler SE, Egloff AM, Wang L, James CD, Hammerman PS, Grandis JR. Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma. PMC Biophys. 2015; 10(2):e0117781. PMID: 25658924.
        View in: PubMed
      22. Hammerman PS, Hayes DN, Grandis JR. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov. 2015 Mar; 5(3):239-44. PMID: 25643909.
        View in: PubMed
      23. Dixit R, Weissfeld JL, Wilson DO, Balogh P, Sufka P, Siegfried JM, Grandis JR, Diergaarde B. Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: Results from the Pittsburgh Lung Screening Study. Cancer. 2015 May 1; 121(9):1431-5. PMID: 25559556.
        View in: PubMed
      24. Fung C, Zhou P, Joyce S, Trent K, Yuan JM, Grandis JR, Weissfeld JL, Romkes M, Weeks DE, Egloff AM. Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma. Cancer Lett. 2015 Feb 28; 357(2):549-56. PMID: 25511740.
        View in: PubMed
      25. Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res. 2015 Feb 1; 21(3):526-33. PMID: 25424855.
        View in: PubMed
      26. Du Y, Grandis JR. Receptor-type protein tyrosine phosphatases in cancer. Chin J Cancer. 2015 Feb 5; 34(2):61-9. PMID: 25322863.
        View in: PubMed
      27. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15544-9. PMID: 25313082; PMCID: PMC4217452 [Available on 04/28/15].
      28. LaPorte MG, da Paz Lima DJ, Zhang F, Sen M, Grandis JR, Camarco D, Hua Y, Johnston PA, Lazo JS, Resnick LO, Wipf P, Huryn DM. 2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. Bioorg Med Chem Lett. 2014 Nov 1; 24(21):5081-5. PMID: 25288188; PMCID: PMC4250329 [Available on 11/01/15].
      29. Peyser ND, Grandis JR. Genetic mutations in head and neck cancer: utilizing existing treatments. Pharmacogenomics. 2014 Sep; 15(12):1553-5. PMID: 25340729.
        View in: PubMed
      30. Nakajima EC, Laymon C, Oborski M, Hou W, Wang L, Grandis JR, Ferris RL, Mountz JM, Van Houten B. Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions. PLoS One. 2014; 9(8):e102452. PMID: 25127378; PMCID: PMC4134191.
      31. Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, Seethala RR, Wang L, Shin DM, Argiris A, Yang D, Mehra R, Ridge JA, Patel UA, Burtness BA, Forastiere AA. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res. 2014 Oct 1; 20(19):5041-51. PMID: 25107914; PMCID: PMC4184913 [Available on 10/01/15].
      32. Gross AM, Orosco RK, Shen JP, Egloff AM, Carter H, Hofree M, Choueiri M, Coffey CS, Lippman SM, Hayes DN, Cohen EE, Grandis JR, Nguyen QT, Ideker T. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014 Sep; 46(9):939-43. PMID: 25086664; PMCID: PMC4146706 [Available on 03/01/15].
      33. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest. 2014 Sep 2; 124(9):3741-56. PMID: 25061874; PMCID: PMC4151226.
      34. Gough AH, Chen N, Shun TY, Lezon TR, Boltz RC, Reese CE, Wagner J, Vernetti LA, Grandis JR, Lee AV, Stern AM, Schurdak ME, Taylor DL. Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. PLoS One. 2014; 9(7):e102678. PMID: 25036749; PMCID: PMC4103836.
      35. Shiwarski DJ, Shao C, Bill A, Kim J, Xiao D, Bertrand CA, Seethala RS, Sano D, Myers JN, Ha P, Grandis J, Gaither LA, Puthenveedu MA, Duvvuri U. To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN. Clin Cancer Res. 2014 Sep 1; 20(17):4673-88. PMID: 24919570; PMCID: PMC4160843 [Available on 09/01/15].
      36. Bauman JE, Grandis JR. Targeting secondary immune responses to cetuximab: CD137 and the outside story. J Clin Invest. 2014 Jun 2; 124(6):2371-5. PMID: 24837438; PMCID: PMC4089450 [Available on 01/01/15].
      37. Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol. 2014 Oct; 8(7):1220-30. PMID: 24816188; PMCID: PMC4198498 [Available on 10/01/15].
      38. D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10. PMID: 24326607; PMCID: PMC3999230 [Available on 04/15/15].
      39. Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3289-98. PMID: 24727329; PMCID: PMC4104657 [Available on 06/15/15].
      40. Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR. Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med. 2014; 20:46-56. PMID: 24395569; PMCID: PMC3951464.
      41. Lei Y, Lui VW, Grandis JR, Egloff AM. Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma. PLoS One. 2014; 9(1):e85619. PMID: 24465623; PMCID: PMC3897487.
      42. Li H, Wawrose JS, Gooding WE, Garraway LA, Lui VW, Peyser ND, Grandis JR. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Mol Cancer Res. 2014 Apr; 12(4):571-82. PMID: 24425785; PMCID: PMC3989421 [Available on 04/01/15].
      43. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1114-9. PMID: 24395800; PMCID: PMC3903220.
      44. Klein JD, Sano D, Sen M, Myers JN, Grandis JR, Kim S. STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma. PLoS One. 2014; 9(1):e81819. PMID: 24404126; PMCID: PMC3880270.
      45. Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, Kim SW, Luvison A, Miller M, Nikiforova MN. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer. 2013; 13:602. PMID: 24341335; PMCID: PMC3878565.
      46. Du Y, Peyser ND, Grandis JR. Integration of molecular targeted therapy with radiation in head and neck cancer. Pharmacol Ther. 2014 Apr; 142(1):88-98. PMID: 24280066.
        View in: PubMed
      47. Sok JC, Lee JA, Dasari S, Joyce S, Contrucci SC, Egloff AM, Trevelline BK, Joshi R, Kumari N, Grandis JR, Thomas SM. Collagen type XI a1 facilitates head and neck squamous cell cancer growth and invasion. Br J Cancer. 2013 Dec 10; 109(12):3049-56. PMID: 24231953; PMCID: PMC3859935 [Available on 12/10/14].
      48. Yazbeck VY, Li C, Grandis JR, Zang Y, Johnson DE. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncol. 2014 Feb; 50(2):120-7. PMID: 24216166; PMCID: PMC3944051 [Available on 02/01/15].
      49. Johnston PA, Sen M, Hua Y, Camarco D, Shun TY, Lazo JS, Grandis JR. High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol. 2014 Jan-Feb; 12(1):55-79. PMID: 24127660; PMCID: PMC3934522 [Available on 02/01/15].
      50. Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, Müller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, Beitler JJ, Nannapaneni S, Shin HJ, Grandis JR, Khuri FR, Chen ZG, Shin DM. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila). 2014 Mar; 7(3):283-91. PMID: 24085777.
        View in: PubMed
      51. Peyser ND, Grandis JR. Critical analysis of the potential for targeting STAT3 in human malignancy. Onco Targets Ther. 2013; 6:999-1010. PMID: 23935373; PMCID: PMC3735336.
      52. Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene. 2014 May 29; 33(22):2846-56. PMID: 23851501; PMCID: PMC4115609.
      53. Troy JD, Weissfeld JL, Youk AO, Thomas S, Wang L, Grandis JR. Expression of EGFR, VEGF, and NOTCH1 suggest differences in tumor angiogenesis in HPV-positive and HPV-negative head and neck squamous cell carcinoma. Head Neck Pathol. 2013 Dec; 7(4):344-55. PMID: 23645351; PMCID: PMC3824798.
      54. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013 Jul; 3(7):761-9. PMID: 23619167; PMCID: PMC3710532.
      55. Troy JD, Grandis JR, Youk AO, Diergaarde B, Romkes M, Weissfeld JL. Childhood passive smoke exposure is associated with adult head and neck cancer. Cancer Epidemiol. 2013 Aug; 37(4):417-23. PMID: 23619143; PMCID: PMC3706460.
      56. Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, Grandis JR. Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiol. 2013 Aug; 37(4):505-11. PMID: 23523331; PMCID: PMC3690299.
      57. Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, Brandes JC, Grist WJ, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, Chen ZG. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res. 2013 Mar 1; 19(5):1244-56. PMID: 23422093; PMCID: PMC3693760.
      58. Romick-Rosendale LE, Lui VW, Grandis JR, Wells SI. The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutat Res. 2013 Mar-Apr; 743-744:78-88. PMID: 23333482; PMCID: PMC3661751.
      59. Mason NS, Lopresti BJ, Ruszkiewicz J, Dong X, Joyce S, Leef G, Sen M, Wahed AS, Mathis CA, Grandis JR, Thomas SM. Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. Am J Nucl Med Mol Imaging. 2013; 3(1):16-31. PMID: 23342298; PMCID: PMC3545366.
      60. Pendleton KP, Grandis JR, et al. Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. Clin Med Insights Ther. 2013; 2013(5). PMID: 24273416.
        View in: PubMed
      61. Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res. 2013 Jan 15; 19(2):380-92. PMID: 23213056; PMCID: PMC3549019.
      62. Thomas SM, Sahu B, Rapireddy S, Bahal R, Wheeler SE, Procopio EM, Kim J, Joyce SC, Contrucci S, Wang Y, Chiosea SI, Lathrop KL, Watkins S, Grandis JR, Armitage BA, Ly DH. Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models. ACS Chem Biol. 2013 Feb 15; 8(2):345-52. PMID: 23113581; PMCID: PMC3684443.
      63. Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia. 2012 Nov; 14(11):1005-14. PMID: 23226094; PMCID: PMC3514742.
      64. Sen M, Grandis JR. Nucleic acid-based approaches to STAT inhibition. JAKSTAT. 2012 Oct 1; 1(4):285-91. PMID: 24058785; PMCID: PMC3670286.
      65. Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012 Dec; 8(12):1873-4. PMID: 22995770; PMCID: PMC3541310.
      66. Fung C, Chen X, Grandis JR, Duvvuri U. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biol Ther. 2012 Dec; 13(14):1417-24. PMID: 22954701; PMCID: PMC3542232.
      67. Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res. 2012 Oct 15; 18(20):5639-49. PMID: 22929803; PMCID: PMC3473099.
      68. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013 Jan; 24(1):220-5. PMID: 22898037; PMCID: PMC3525135.
      69. Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther. 2012 Aug; 13(10):935-45. PMID: 22785204; PMCID: PMC3414414.
      70. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res. 2012 Sep 15; 18(18):4986-96. PMID: 22825581; PMCID: PMC3445706.
      71. Egloff AM, Grandis JR. Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res. 2012 Oct 1; 18(19):5188-95. PMID: 22773520; PMCID: PMC3463728.
      72. Lui VW, Grandis JR. Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer. Head Neck Pathol. 2012 Jul; 6 Suppl 1:S91-7. PMID: 22782228; PMCID: PMC3394163.
      73. Moskowitz HS, Gooding WE, Thomas SM, Freilino ML, Gross N, Argiris A, Grandis JR, Ferris RL. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncol. 2012 Nov; 48(11):1136-45. PMID: 22732263; PMCID: PMC3462892.
      74. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012 Aug; 2(8):694-705. PMID: 22719020; PMCID: PMC3668699.
      75. Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, Rock JR, Harfe BD, Henson BJ, Kunzelmann K, Schreiber R, Seethala RS, Egloff AM, Chen X, Lui VW, Grandis JR, Gollin SM. TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res. 2012 Jul 1; 72(13):3270-81. PMID: 22564524; PMCID: PMC3694774.
      76. Wheeler SE, Morariu EM, Bednash JS, Otte CG, Seethala RR, Chiosea SI, Grandis JR. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res. 2012 May 15; 18(10):2850-60. PMID: 22490227; PMCID: PMC3433855.
      77. Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther. 2012 Jun; 11(6):1236-46. PMID: 22491800; PMCID: PMC3413198.
      78. Egloff AM, Liu X, Davis AL, Trevelline BK, Vuga M, Siegfried JM, Grandis JR. Elevated gastrin-releasing peptide receptor mRNA expression in buccal mucosa: association with head and neck squamous cell carcinoma. Head Neck. 2013 Feb; 35(2):270-9. PMID: 22431275; PMCID: PMC3553276.
      79. Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res. 2012 Apr 15; 18(8):2278-89. PMID: 22351687; PMCID: PMC3430124.
      80. Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head Neck. 2012 Sep; 34(9):1269-76. PMID: 22307735; PMCID: PMC3675227.
      81. Egloff AM, Gaither Davis A, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM. Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study. Respir Res. 2012; 13:9. PMID: 22296774; PMCID: PMC3305653.
      82. Dedhia RC, Grandis JR, Fontes PA, Johnson JT, Weissfeld J. Screening for head and neck cancer in liver transplant candidates: a review of 11 years of experience at the University of Pittsburgh. Laryngoscope. 2012 Mar; 122(3):539-42. PMID: 22183711; PMCID: PMC3391608.
      83. Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis J, Romkes M, Weissfeld JL. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer Epidemiol Biomarkers Prev. 2011 Nov; 20(11):2429-37. PMID: 21890746; PMCID: PMC3210907.
      84. Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF, Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol. 2011 Oct; 47(10):961-6. PMID: 21889392; PMCID: PMC3402506.
      85. Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Invest New Drugs. 2012 Aug; 30(4):1575-84. PMID: 21881918; PMCID: PMC3402509.
      86. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res. 2011 Dec 1; 17(23):7248-64. PMID: 21868764; PMCID: PMC3229662.
      87. Thomas SM, Grandis JR. Targeting mesenchymal exaptation to mitigate tumor growth. Cell Cycle. 2011 Aug 15; 10(16):2626-7. PMID: 21836394; PMCID: PMC3918968.
      88. Sahu N, Grandis JR. New advances in molecular approaches to head and neck squamous cell carcinoma. Anticancer Drugs. 2011 Aug; 22(7):656-64. PMID: 21178766; PMCID: PMC3080467.
      89. Rwigema JC, Heron DE, Ferris RL, Andrade RS, Gibson MK, Yang Y, Ozhasoglu C, Argiris AE, Grandis JR, Burton SA. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol. 2011 Aug; 34(4):372-9. PMID: 20859194; PMCID: PMC3177149.
      90. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60. PMID: 21798893; PMCID: PMC3415217.
      91. Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res. 2011 Sep 15; 17(18):5935-44. PMID: 21791633; PMCID: PMC3426303.
      92. Langevin SM, Grandis JR, Taioli E. Female hormonal and reproductive factors and head and neck squamous cell carcinoma risk. Cancer Lett. 2011 Nov 28; 310(2):216-21. PMID: 21802839; PMCID: PMC3169650.
      93. Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, Bristow R, Powis G, Hill RP, Le QT, Pelroy R, Mohla S, Bernhard EJ. Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010. Radiat Res. 2011 Sep; 176(3):e0016-21. PMID: 21867428.
        View in: PubMed
      94. Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D'Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2011 Aug 15; 17(16):5513-22. PMID: 21737503; PMCID: PMC3156890.
      95. Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clin Cancer Res. 2011 Aug 1; 17(15):4996-5004. PMID: 21653688; PMCID: PMC3149755.
      96. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res. 2011 Jul 1; 17(13):4425-38. PMID: 21622718; PMCID: PMC3138116.
      97. Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol. 2011 Nov; 22(11):2482-8. PMID: 21363880; PMCID: PMC3200222.
      98. Ma HH, Ziegler J, Li C, Sepulveda A, Bedeir A, Grandis J, Lentzsch S, Mapara MY. Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. Cell Immunol. 2011; 268(1):37-46. PMID: 21376308; PMCID: PMC3061826.
      99. Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Mol Interv. 2011 Feb; 11(1):18-26. PMID: 21441118; PMCID: PMC3063716.
      100. Feinstein TM, Lai SY, Lenzner D, Gooding W, Ferris RL, Grandis JR, Myers EN, Johnson JT, Heron DE, Argiris A. Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. Head Neck. 2011 Mar; 33(3):318-23. PMID: 21284048; PMCID: PMC4135528.
      101. Egloff AM, Grandis JR. Response to combined molecular targeting: defining the role of P-STAT3. Clin Cancer Res. 2011 Feb 1; 17(3):393-5. PMID: 21266530; PMCID: PMC3149866.
      102. Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila). 2011 Feb; 4(2):230-7. PMID: 21163936; PMCID: PMC3076320.
      103. Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol. 2010 Dec 20; 28(36):5294-300. PMID: 21079141; PMCID: PMC3018361.
      104. Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, Landreneau RJ, Grandis JR, Siegfried JM. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 2011 Jan 1; 17(1):154-64. PMID: 21062926; PMCID: PMC3064257.
      105. Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, Kelly L, Seethala RR, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer. 2011 Apr 1; 117(7):1454-62. PMID: 21425146; PMCID: PMC3117118.
      106. Ragin CC, Langevin SM, Marzouk M, Grandis J, Taioli E. Determinants of head and neck cancer survival by race. Head Neck. 2011 Aug; 33(8):1092-8. PMID: 20967872; PMCID: PMC3380362.
      107. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck. 2010 Oct; 32(10):1412-21. PMID: 20848399; PMCID: PMC2946515.
      108. Diergaarde B, Grandis JR. Human papillomavirus and head and neck cancer. Oncology (Williston Park). 2010 Sep; 24(10):927, 933. PMID: 21138174.
        View in: PubMed
      109. Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 2010 Sep; 15(3):355-73. PMID: 20557270; PMCID: PMC3133968.
      110. Wheeler SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene. 2010 Sep 16; 29(37):5135-45. PMID: 20622897; PMCID: PMC2940981.
      111. Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, Grandis JR, Gaither Davis A, Bigbee WL, Rom W, Sidransky D. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res. 2010 Jul 1; 16(13):3463-72. PMID: 20592015; PMCID: PMC2899894.
      112. Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010 Jul; 3(7):800-9. PMID: 20570883; PMCID: PMC2900459.
      113. Yang W, Cai Q, Lui VW, Everley PA, Kim J, Bhola N, Quesnelle KM, Zetter BR, Steen H, Freeman MR, Grandis JR. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. J Proteome Res. 2010 Jun 4; 9(6):3073-82. PMID: 20426488; PMCID: PMC3149825.
      114. Cassell A, Grandis JR. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2010 Jun; 19(6):709-22. PMID: 20415598; PMCID: PMC2947445.
      115. Passero VA, Branstetter BF, Shuai Y, Heron DE, Gibson MK, Lai SY, Kim SW, Grandis JR, Ferris RL, Johnson JT, Argiris A. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol. 2010 Nov; 21(11):2278-83. PMID: 20430907.
        View in: PubMed
      116. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010 May 1; 16(9):2489-95. PMID: 20406834; PMCID: PMC2887084.
      117. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010 May 1; 16(9):2571-9. PMID: 20388852; PMCID: PMC2871379.
      118. Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res. 2010 Apr 15; 16(8):2427-34. PMID: 20371693; PMCID: PMC3030188.
      119. Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis. 2010 May; 31(5):864-70. PMID: 20197299; PMCID: PMC2864416.
      120. Kwok J, Langevin SM, Argiris A, Grandis JR, Gooding WE, Taioli E. The impact of health insurance status on the survival of patients with head and neck cancer. Cancer. 2010 Jan 15; 116(2):476-85. PMID: 19937673; PMCID: PMC3085979.
      121. Klein JD, Grandis JR. The molecular pathogenesis of head and neck cancer. Cancer Biol Ther. 2010 Jan; 9(1):1-7. PMID: 20038820; PMCID: PMC3138532.
      122. Park BJ, Chiosea SI, Grandis JR. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark. 2010; 9(1-6):325-39. PMID: 22112483; PMCID: PMC3409637.
      123. McLaughlin BT, Gokhale AS, Shuai Y, Diacopoulos J, Carrau R, Heron DE, Smith RP, Gibson MK, Ferris RL, Grandis JR, Johnson JT, Argiris A. Management of patients treated with chemoradiotherapy for head and neck cancer without prophylactic feeding tubes: the University of Pittsburgh experience. Laryngoscope. 2010 Jan; 120(1):71-5. PMID: 19877245.
        View in: PubMed
      124. Qi Y, Dhiman HK, Bhola N, Budyak I, Kar S, Man D, Dutta A, Tirupula K, Carr BI, Grandis J, Bar-Joseph Z, Klein-Seetharaman J. Systematic prediction of human membrane receptor interactions. Proteomics. 2009 Dec; 9(23):5243-55. PMID: 19798668; PMCID: PMC3076061.
      125. Thomas SM, Grandis JR. The current state of head and neck cancer gene therapy. Hum Gene Ther. 2009 Dec; 20(12):1565-75. PMID: 19747066; PMCID: PMC2829451.
      126. Amin W, Kang HP, Egloff AM, Singh H, Trent K, Ridge-Hetrick J, Seethala RR, Grandis J, Parwani AV. An informatics supported web-based data annotation and query tool to expedite translational research for head and neck malignancies. BMC Cancer. 2009; 9:396. PMID: 19912644; PMCID: PMC2780457.
      127. Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, Choi GC, Au TC, Ho K, Yau DM, Ma BB, Hui EP, Chan AS, Tsang CM, Tsao SW, Grandis JR, Chan AT. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer. 2009 Oct 15; 125(8):1884-93. PMID: 19588483.
        View in: PubMed
      128. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res. 2009 Nov 1; 15(21):6529-40. PMID: 19825947; PMCID: PMC2783886.
      129. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis. 2009 Nov; 30(11):1848-56. PMID: 19762335; PMCID: PMC2783003.
      130. Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. Mol Cancer Ther. 2009 Aug; 8(8):2211-20. PMID: 19638453; PMCID: PMC2768047.
      131. Egloff AM, Grandis JR. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. J Oncol. 2009; 2009:896407. PMID: 19636423; PMCID: PMC2712676.
      132. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 2009 Jun 1; 15(11):3740-50. PMID: 19470725; PMCID: PMC3159511.
      133. Heron DE, Ferris RL, Karamouzis M, Andrade RS, Deeb EL, Burton S, Gooding WE, Branstetter BF, Mountz JM, Johnson JT, Argiris A, Grandis JR, Lai SY. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009 Dec 1; 75(5):1493-500. PMID: 19464819.
        View in: PubMed
      134. Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene. 2009 Jun 18; 28(24):2348-57. PMID: 19421143; PMCID: PMC2872091.
      135. Grandis JR, Argiris A. Targeting angiogenesis from premalignancy to metastases. Cancer Prev Res (Phila). 2009 Apr; 2(4):291-4. PMID: 19336719.
        View in: PubMed
      136. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother. 2009 Nov; 58(11):1853-64. PMID: 19319529; PMCID: PMC3426289.
      137. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol. 2009 May; 75(5):1231-9. PMID: 19246337; PMCID: PMC2672802.
      138. Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, Mills G, Argiris A, Grandis JR. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol. 2009 Mar 10; 27(8):1235-42. PMID: 19204206; PMCID: PMC2667824.
      139. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol. 2009 Jan; 19(1):63-8. PMID: 19028347; PMCID: PMC3216119.
      140. Zhang W, Bhola N, Kalyankrishna S, Gooding W, Hunt J, Seethala R, Grandis JR, Siegfried JM. Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas. Mol Cancer Res. 2008 Dec; 6(12):1946-56. PMID: 19074839; PMCID: PMC3575100.
      141. Koppikar P, Lui VW, Man D, Xi S, Chai RL, Nelson E, Tobey AB, Grandis JR. Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res. 2008 Dec 1; 14(23):7682-90. PMID: 19047094; PMCID: PMC3422894.
      142. Sok JC, Grandis JR. Genetic screening for oral human papillomavirus infections and cancers of the head and neck. Clin Cancer Res. 2008 Nov 1; 14(21):6723-4. PMID: 18980962.
        View in: PubMed
      143. Zou H, Thomas SM, Yan ZW, Grandis JR, Vogt A, Li LY. Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J. 2009 Feb; 23(2):425-32. PMID: 18832597; PMCID: PMC2638965.
      144. Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE, Grandis JR. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2009 May; 63(6):983-95. PMID: 18766340; PMCID: PMC3422883.
      145. Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res. 2009 Feb 15; 315(4):572-82. PMID: 18778701; PMCID: PMC2657476.
      146. Lin HY, Sun M, Tang HY, Simone TM, Wu YH, Grandis JR, Cao HJ, Davis PJ, Davis FB. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem. 2008 Aug 15; 104(6):2131-42. PMID: 18446786.
        View in: PubMed
      147. Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, Grandis JR. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res. 2008 Jul 1; 14(13):4284-91. PMID: 18594011; PMCID: PMC3428119.
      148. Nozawa H, Howell G, Suzuki S, Zhang Q, Qi Y, Klein-Seetharaman J, Wells A, Grandis JR, Thomas SM. Combined inhibition of PLC{gamma}-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res. 2008 Jul 1; 14(13):4336-44. PMID: 18594017; PMCID: PMC3358699.
      149. Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, Li LY. Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther. 2008 Jun; 7(6):1355-64. PMID: 18524845; PMCID: PMC3426753.
      150. Vokes EE, Cohen EE, Grandis JR. Introduction: head and neck cancer. Semin Oncol. 2008 Jun; 35(3):196-7. PMID: 18544434.
        View in: PubMed
      151. Li C, Li R, Grandis JR, Johnson DE. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther. 2008 Jun; 7(6):1647-55. PMID: 18566236; PMCID: PMC2534142.
      152. Egloff AM, Grandis JR. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol. 2008 Jun; 35(3):286-97. PMID: 18544443; PMCID: PMC2587085.
      153. Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck. 2008 May; 30(5):667-74. PMID: 18383530.
        View in: PubMed
      154. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol. 2008 Jun; 73(6):1632-42. PMID: 18326051; PMCID: PMC3437602.
      155. Argiris A, Karamouzis MV, Johnson JT, Heron DE, Myers E, Eibling D, Cano E, Urba S, Gluckman J, Grandis JR, Wang Y, Agarwala SS. Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer. Laryngoscope. 2008 Mar; 118(3):444-9. PMID: 18091334.
        View in: PubMed
      156. Seethala RR, Gooding WE, Handler PN, Collins B, Zhang Q, Siegfried JM, Grandis JR. Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res. 2008 Mar 1; 14(5):1303-9. PMID: 18316548; PMCID: PMC3424506.
      157. Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE, Johnson DE. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia. 2008 Aug; 22(8):1624-7. PMID: 18305561; PMCID: PMC2596306.
      158. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 2008; 13:1857-65. PMID: 17981673.
        View in: PubMed
      159. Karamouzis MV, Argiris A, Grandis JR. Clinical applications of gene therapy in head and neck cancer. Curr Gene Ther. 2007 Dec; 7(6):446-57. PMID: 18045104.
        View in: PubMed
      160. Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Mol Pharmacol. 2008 Mar; 73(3):627-38. PMID: 18025070.
        View in: PubMed
      161. Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE. Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia. 2007 Oct; 9(10):801-11. PMID: 17971900; PMCID: PMC2040207.
      162. Ferris RL, Grandis JR. NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2007 Oct 1; 13(19):5663-4. PMID: 17908953.
        View in: PubMed
      163. Quesnelle KM, Boehm AL, Grandis JR. STAT-mediated EGFR signaling in cancer. J Cell Biochem. 2007 Oct 1; 102(2):311-9. PMID: 17661350.
        View in: PubMed
      164. Grandis JR, Carbone DP, Rustgi AK. Advances and challenges in aerodigestive epithelial cancer: meeting summary and research opportunities. Cancer Res. 2007 Aug 15; 67(16):7556-8. PMID: 17686829.
        View in: PubMed
      165. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007 Jul 4; 298(1):70-82. PMID: 17609492.
        View in: PubMed
      166. Nelson EG, Grandis JR. Aberrant kinase signaling: lessons from head and neck cancer. Future Oncol. 2007 Jun; 3(3):353-61. PMID: 17547530.
        View in: PubMed
      167. Bigbee WL, Grandis JR, Siegfried JM. Multiple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients. Clin Cancer Res. 2007 Jun 1; 13(11):3107-8. PMID: 17545511.
        View in: PubMed
      168. Zhang W, Weissfeld JL, Romkes M, Land SR, Grandis JR, Siegfried JM. Association of the EGFR intron 1 CA repeat length with lung cancer risk. Mol Carcinog. 2007 May; 46(5):372-80. PMID: 17219440.
        View in: PubMed
      169. Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther. 2007 Apr; 6(4):1414-24. PMID: 17431120.
        View in: PubMed
      170. Moore BA, Albers KM, Davis BM, Grandis JR, Tögel S, Bauer AJ. Altered inflammatory gene expression underlies increased susceptibility to murine postoperative ileus with advancing age. Am J Physiol Gastrointest Liver Physiol. 2007 Jun; 292(6):G1650-9. PMID: 17363464.
        View in: PubMed
      171. Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, Wang Q, Lo Y, Zhou BB, Pan M, Thomas SM, Grandis JR, Zhuo J, Yao W, Newton RC, Friedman SM, Scherle PA, Vaddi K. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1892-902. PMID: 17363546.
        View in: PubMed
      172. Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, Childs E, Freilino M, Grandis JR. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol. 2007 May; 71(5):1435-43. PMID: 17325127.
        View in: PubMed
      173. Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp Cell Res. 2007 Apr 15; 313(7):1361-72. PMID: 17349623.
        View in: PubMed
      174. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, Ferris RL, Lai SY. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck. 2007 Feb; 29(2):163-88. PMID: 17312569.
        View in: PubMed
      175. Nelson AD, Grandis JR. The role of CD44 in HNSCC. Cancer Biol Ther. 2007 Jan; 6(1):125-6. PMID: 17297303.
        View in: PubMed
      176. Grandis JR. Established and emerging concepts in epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2007; 69(2 Suppl):S22-4. PMID: 17848285.
        View in: PubMed
      177. Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res. 2006 Dec 15; 66(24):11831-9. PMID: 17178880.
        View in: PubMed
      178. Lai SY, Grandis JR. Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol. 2006 Oct 10; 24(29):4675-6. PMID: 17028292.
        View in: PubMed
      179. Egloff AM, Grandis J. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets. 2006 Oct; 10(5):639-47. PMID: 16981821.
        View in: PubMed
      180. Voynov G, Heron DE, Burton S, Grandis J, Quinn A, Ferris R, Ozhasoglu C, Vogel W, Johnson J. Frameless stereotactic radiosurgery for recurrent head and neck carcinoma. Technol Cancer Res Treat. 2006 Oct; 5(5):529-35. PMID: 16981796.
        View in: PubMed
      181. Grandis JR. Prognostic biomarkers in head and neck cancer. Clin Cancer Res. 2006 Sep 1; 12(17):5005-6. PMID: 16951212.
        View in: PubMed
      182. Zhang W, Stabile LP, Keohavong P, Romkes M, Grandis JR, Traynor AM, Siegfried JM. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol. 2006 Sep; 1(7):635-47. PMID: 17409930.
        View in: PubMed
      183. Elsheikh MN, Rinaldo A, Hamakawa H, Mahfouz ME, Rodrigo JP, Brennan J, Devaney KO, Grandis JR, Ferlito A. Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck. 2006 Sep; 28(9):842-9. PMID: 16691557.
        View in: PubMed
      184. Grandis JR, Battey JF, Califf RM, Chole RA, Gantz BJ, Gates GA, Gorelic L, Hannley MT, Hardwick KS, Harris JP, Kapoor WN, Lai SY, Lalwani AK, Minor LB, Nadol JP, Post JC, Roland PS, Schechter AM, Schuller DE, Sklare DA, Wackym PA, Weber RS, Weymuller EA, Wolf GT, Woodson GE. Research education and training in otolaryngology: meeting summary and research opportunities. Otolaryngol Head Neck Surg. 2006 Sep; 135(3):361-7. PMID: 16949965.
        View in: PubMed
      185. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006 Sep 1; 12(17):5064-73. PMID: 16951222.
        View in: PubMed
      186. Zhou W, Grandis JR, Wells A. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br J Cancer. 2006 Jul 17; 95(2):164-71. PMID: 16804520; PMCID: PMC2360627.
      187. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006 Jun 10; 24(17):2666-72. PMID: 16763281.
        View in: PubMed
      188. Forastiere AA, Trotti A, Pfister DG, Grandis JR. Head and neck cancer: recent advances and new standards of care. J Clin Oncol. 2006 Jun 10; 24(17):2603-5. PMID: 16763271.
        View in: PubMed
      189. Ferguson BJ, Grandis JR. Women in otolaryngology: closing the gender gap. Curr Opin Otolaryngol Head Neck Surg. 2006 Jun; 14(3):159-63. PMID: 16728893.
        View in: PubMed
      190. Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A. 2006 May 2; 103(18):6901-6. PMID: 16641105; PMCID: PMC1458991.
      191. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther. 2006 Mar; 6(3):231-41. PMID: 16503733.
        View in: PubMed
      192. Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, Grandis JR. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst. 2006 Feb 1; 98(3):181-9. PMID: 16449678.
        View in: PubMed
      193. Chai RL, Grandis JR. Advances in molecular diagnostics and therapeutics in head and neck cancer. Curr Treat Options Oncol. 2006 Jan; 7(1):3-11. PMID: 16343364.
        View in: PubMed
      194. Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem Pharmacol. 2005 Nov 25; 70(11):1685-96. PMID: 16207485.
        View in: PubMed
      195. Begleiter A, Norman A, Leitao D, Cabral T, Hewitt D, Pan S, Grandis JR, Siegfried JM, El-Sayed S, Sutherland D, Ross DA, Kerr PD. Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol. 2005 Oct; 41(9):927-33. PMID: 16054862.
        View in: PubMed
      196. Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG, Ferris RL. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene. 2005 Sep 1; 24(38):5897-904. PMID: 16007209.
        View in: PubMed
      197. Howell GM, Grandis JR. Molecular mediators of metastasis in head and neck squamous cell carcinoma. Head Neck. 2005 Aug; 27(8):710-7. PMID: 15952195.
        View in: PubMed
      198. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005 Jun 23; 24(27):4442-9. PMID: 15856028.
        View in: PubMed
      199. Buch S, Zhu B, Davis AG, Odom D, Siegfried JM, Grandis JR, Romkes M. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005 Apr; 42(4):222-8. PMID: 15754315.
        View in: PubMed
      200. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, Siegfried JM. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia. 2005 Apr; 7(4):426-31. PMID: 15967120; PMCID: PMC1501149.
      201. Hathaway B, Landsittel DP, Gooding W, Whiteside TL, Grandis JR, Siegfried JM, Bigbee WL, Ferris RL. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope. 2005 Mar; 115(3):522-7. PMID: 15744170.
        View in: PubMed
      202. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. 2005 Feb 15; 65(4):1459-70. PMID: 15735034.
        View in: PubMed
      203. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene. 2005 Feb 3; 24(6):970-9. PMID: 15592503.
        View in: PubMed
      204. Coppelli FM, Grandis JR. Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Curr Pharm Des. 2005; 11(22):2825-40. PMID: 16101440.
        View in: PubMed
      205. Riedel F, Götte K, Hörmann K, Grandis JR. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy. Adv Otorhinolaryngol. 2005; 62:103-20. PMID: 15608422.
        View in: PubMed
      206. Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol. 2004 Dec; 31(6):734-43. PMID: 15599851.
        View in: PubMed
      207. Gorelik E, Edwards RP, Feng X, Marrangoni AM, Grandis JR, Drenning SD, Velikokhatnaya L, Kwon JA, Lokshin AE. IL-12 receptor-mediated upregulation of FasL in human ovarian carcinoma cells. Int J Cancer. 2004 Nov 20; 112(4):620-7. PMID: 15382042.
        View in: PubMed
      208. Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA, Mohla S. Head and neck cancer: meeting summary and research opportunities. Cancer Res. 2004 Nov 1; 64(21):8126-9. PMID: 15520225.
        View in: PubMed
      209. Thomas SM, Zeng Q, Epperly MW, Gooding WE, Pastan I, Wang QC, Greenberger J, Grandis JR. Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38. Clin Cancer Res. 2004 Oct 15; 10(20):7079-87. PMID: 15501988.
        View in: PubMed
      210. Andrews GA, Xi S, Pomerantz RG, Lin CJ, Gooding WE, Wentzel AL, Wu L, Sidransky D, Grandis JR. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck. 2004 Oct; 26(10):870-7. PMID: 15390206.
        View in: PubMed
      211. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 2004 Sep 1; 64(17):6166-73. PMID: 15342401.
        View in: PubMed
      212. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004 Sep 1; 10(17):5930-9. PMID: 15355926.
        View in: PubMed
      213. Grandis JR, Gooding WE, Zamboni BA, Wagener MM, Drenning SD, Miller L, Doyle KJ, Mackinnon SE, Wagner RL. The gender gap in a surgical subspecialty: analysis of career and lifestyle factors. Arch Otolaryngol Head Neck Surg. 2004 Jun; 130(6):695-702. PMID: 15210549.
        View in: PubMed
      214. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev. 2004 May; 30(3):255-68. PMID: 15059649.
        View in: PubMed
      215. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004 Apr; 102(1):37-46. PMID: 15056497.
        View in: PubMed
      216. Schwarz NT, Kalff JC, Türler A, Speidel N, Grandis JR, Billiar TR, Bauer AJ. Selective jejunal manipulation causes postoperative pan-enteric inflammation and dysmotility. Gastroenterology. 2004 Jan; 126(1):159-69. PMID: 14699497.
        View in: PubMed
      217. Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, Grandis JR. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2003 Oct 15; 9(13):5028-35. PMID: 14581378.
        View in: PubMed
      218. Xi S, Zhang Q, Gooding WE, Smithgall TE, Grandis JR. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 2003 Oct 15; 63(20):6763-71. PMID: 14583472.
        View in: PubMed
      219. Moore BA, Türler A, Pezzone MA, Dyer K, Grandis J, Bauer AJ. Tyrphostin AG 126 inhibits development of postoperative ileus induced by surgical manipulation of murine colon. Am J Physiol Gastrointest Liver Physiol. 2004 Feb; 286(2):G214-24. PMID: 14512290.
        View in: PubMed
      220. Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, Grandis JR. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene. 2003 Sep 18; 22(40):6183-93. PMID: 13679857.
        View in: PubMed
      221. Lango M, Wentzel AL, Song JI, Xi S, Johnson DE, Lamph WW, Miller L, Grandis JR. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells. Clin Cancer Res. 2003 Sep 15; 9(11):4205-13. PMID: 14519647.
        View in: PubMed
      222. Riedel F, Götte K, Li M, Hörmann K, Grandis JR. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo. Int J Oncol. 2003 Sep; 23(3):577-83. PMID: 12888890.
        View in: PubMed
      223. Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res. 2003 Sep 1; 63(17):5629-35. PMID: 14500405.
        View in: PubMed
      224. Lui VW, Wentzel AL, Xiao D, Lew KL, Singh SV, Grandis JR. Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma. Carcinogenesis. 2003 Oct; 24(10):1705-12. PMID: 12896907.
        View in: PubMed
      225. Thomas SM, Zeng Q, Dyer KF, Suscovich TJ, Kanter PM, Whalen JD, Watkins SF, Grandis JR. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Ther. 2003 Jul; 10(7):518-28. PMID: 12833132.
        View in: PubMed
      226. Steinman RA, Wentzel A, Lu Y, Stehle C, Grandis JR. Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2. Oncogene. 2003 Jun 5; 22(23):3608-15. PMID: 12789269.
        View in: PubMed
      227. Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):367-80. PMID: 12820779.
        View in: PubMed
      228. Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, Kamens J, Grandis JR. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem. 2003 Aug 22; 278(34):31574-83. PMID: 12771142.
        View in: PubMed
      229. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003 Apr 1; 100(7):4138-43. PMID: 12640143; PMCID: PMC153061.
      230. Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep. 2003 Mar; 5(2):140-6. PMID: 12583831.
        View in: PubMed
      231. Miranda MB, Dyer KF, Grandis JR, Johnson DE. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells. Leukemia. 2003 Feb; 17(2):390-400. PMID: 12592339.
        View in: PubMed
      232. Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res. 2003 Jan; 82(1):11-6. PMID: 12508038.
        View in: PubMed
      233. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck. 2003 Jan; 25(1):67-73. PMID: 12478546.
        View in: PubMed
      234. Wells A, Grandis JR. Phospholipase C-gamma1 in tumor progression. Clin Exp Metastasis. 2003; 20(4):285-90. PMID: 12856715.
        View in: PubMed
      235. Li M, Ye C, Feng C, Riedel F, Liu X, Zeng Q, Grandis JR. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res. 2002 Nov; 8(11):3570-8. PMID: 12429648.
        View in: PubMed
      236. Schwarz NT, Engel B, Eskandari MK, Kalff JC, Grandis JR, Bauer AJ. Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus. Gastroenterology. 2002 Aug; 123(2):586-98. PMID: 12145811.
        View in: PubMed
      237. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, Grandis JR. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002 Aug; 13(8):355-62. PMID: 12193474.
        View in: PubMed
      238. Riedel F, Götte K, Li M, Hörmann K, Grandis JR. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration. Int J Oncol. 2002 Jul; 21(1):11-6. PMID: 12063543.
        View in: PubMed
      239. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. Stat3 activation in prostatic carcinomas. Prostate. 2002 Jun 1; 51(4):241-6. PMID: 11987152.
        View in: PubMed
      240. Zeng Q, Kanter PM, Dhir R, Gooding WE, Huang L, Grandis JR. Lack of toxicity of EGFR antisense gene therapy. J Exp Ther Oncol. 2002 May-Jun; 2(3):174-86. PMID: 12415634.
        View in: PubMed
      241. Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC, Smithgall TE, Grandis JR. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene. 2002 Apr 25; 21(18):2846-53. PMID: 11973644.
        View in: PubMed
      242. Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F, Grandis JR, Gao AC. Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol. 2002 Apr; 167(4):1859-62. PMID: 11912448.
        View in: PubMed
      243. Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR. Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2002 Mar 6; 94(5):375-83. PMID: 11880476.
        View in: PubMed
      244. Lui VW, Grandis JR. EGFR-mediated cell cycle regulation. Anticancer Res. 2002 Jan-Feb; 22(1A):1-11. PMID: 12017269.
        View in: PubMed
      245. Fan CY, Melhem MF, Hosal AS, Grandis JR, Barnes EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg. 2001 Sep; 127(9):1075-9. PMID: 11556855.
        View in: PubMed
      246. Song JI, Lango MN, Hwang JD, Drenning SD, Zeng Q, Lamph WW, Grandis JR. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res. 2001 Aug 1; 61(15):5919-25. PMID: 11479234.
        View in: PubMed
      247. Lango MN, Shin DM, Grandis JR. Targeting growth factor receptors: integration of novel therapeutics in the management of head and neck cancer. Curr Opin Oncol. 2001 May; 13(3):168-75. PMID: 11307060.
        View in: PubMed
      248. Simons JP, Johnson JT, Yu VL, Vickers RM, Gooding WE, Myers EN, Pou AM, Wagner RL, Grandis JR. The role of topical antibiotic prophylaxis in patients undergoing contaminated head and neck surgery with flap reconstruction. Laryngoscope. 2001 Feb; 111(2):329-35. PMID: 11210884.
        View in: PubMed
      249. Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res. 2000 Jul; 6(7):2794-802. PMID: 10914726.
        View in: PubMed
      250. Zeng Q, Smith DC, Suscovich TJ, Gooding WE, Trump DL, Grandis JR. Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin Cancer Res. 2000 Jun; 6(6):2245-51. PMID: 10873074.
        View in: PubMed
      251. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 2000 May 15; 19(21):2489-95. PMID: 10851047.
        View in: PubMed
      252. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4227-32. PMID: 10760290; PMCID: PMC18206.
      253. Snyderman CH, Goldman SA, Carrau RL, Ferguson BJ, Grandis JR. Endoscopic sphenopalatine artery ligation is an effective method of treatment for posterior epistaxis. Am J Rhinol. 1999 Mar-Apr; 13(2):137-40. PMID: 10219443.
        View in: PubMed
      254. Drenning SD, Marcovitch AJ, Johnson DE, Melhem MF, Tweardy DJ, Grandis JR. Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium. Clin Cancer Res. 1998 Nov; 4(11):2913-21. PMID: 9829760.
        View in: PubMed
      255. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest. 1998 Oct 1; 102(7):1385-92. PMID: 9769331; PMCID: PMC508986.
      256. Runge D, Runge DM, Drenning SD, Bowen WC, Grandis JR, Michalopoulos GK. Growth and differentiation of rat hepatocytes: changes in transcription factors HNF-3, HNF-4, STAT-3, and STAT-5. Biochem Biophys Res Commun. 1998 Sep 29; 250(3):762-8. PMID: 9784420.
        View in: PubMed
      257. Grandis JR, Zeng Q, Drenning SD, Tweardy DJ. Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line. Int J Oncol. 1998 Aug; 13(2):375-8. PMID: 9664135.
        View in: PubMed
      258. He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, Grandis JR. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst. 1998 Jul 15; 90(14):1080-7. PMID: 9672256.
        View in: PubMed
      259. Yellon RF, Szeremeta W, Grandis JR, Diguisseppe P, Dickman PS. Subglottic injury, gastric juice, corticosteroids, and peptide growth factors in a porcine model. Laryngoscope. 1998 Jun; 108(6):854-62. PMID: 9628501.
        View in: PubMed
      260. Grandis JR, Chakraborty A, Zeng Q, Melhem MF, Tweardy DJ. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem. 1998 Apr 1; 69(1):55-62. PMID: 9513046.
        View in: PubMed
      261. Pitman KT, Agarwala SS, Cano ER, Eibling DE, Fagan JJ, Grandis JR, Johnson JT, Myers EN, Russavage JM, Snyderman CH, Weismann JL. Tumor Board Conference from the University of Pittsburgh. Oncology (Williston Park). 1997 Jul; 11(7):1033-9. PMID: 9251122.
        View in: PubMed
      262. Grandis JR, Perez-Perez GI, Yu VL, Johnson JT, Blaser MJ. Lack of serologic evidence for Helicobacter pylori infection in head and neck cancer. Head Neck. 1997 May; 19(3):216-8. PMID: 9142522.
        View in: PubMed
      263. Yellon RF, Szeremeta W, Grandis JR, Diguisseppe P, Dickman PS. Role of subglottic injury, gastric juice, and peptide growth factors in a porcine model. Int Anesthesiol Clin. 1997; 35(3):115-25. PMID: 9361983.
        View in: PubMed
      264. Grandis JR, Curtin HD, Yu VL. Necrotizing (malignant) external otitis: prospective comparison of CT and MR imaging in diagnosis and follow-up. Radiology. 1995 Aug; 196(2):499-504. PMID: 7617867.
        View in: PubMed
      265. Grandis JR, Chang MJ, Yu WD, Johnson CS. Antitumor activity of interleukin-1 alpha and cisplatin in a murine model system. Arch Otolaryngol Head Neck Surg. 1995 Feb; 121(2):197-200. PMID: 7840928.
        View in: PubMed
      266. Grandis JR, Vickers RM, Rihs JD, Yu VL, Johnson JT. Efficacy of topical amoxicillin plus clavulanate/ticarcillin plus clavulanate and clindamycin in contaminated head and neck surgery: effect of antibiotic spectra and duration of therapy. J Infect Dis. 1994 Sep; 170(3):729-32. PMID: 8077738.
        View in: PubMed
      267. Grandis JR, Vickers RM, Rihs JD, Yu VL, Wagner RL, Kachman KK, Johnson JT. The efficacy of topical antibiotic prophylaxis for contaminated head and neck surgery. Laryngoscope. 1994 Jun; 104(6 Pt 1):719-24. PMID: 8196446.
        View in: PubMed
      268. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993 Aug 1; 53(15):3579-84. PMID: 8339264.
        View in: PubMed
      269. Grandis JR, Hirsch BE, Yu VL. Simultaneous presentation of malignant external otitis and temporal bone cancer. Arch Otolaryngol Head Neck Surg. 1993 Jun; 119(6):687-9. PMID: 8499104.
        View in: PubMed
      270. Grandis JR, Hirsch BE, Wagener MM. Treatment of idiopathic sudden sensorineural hearing loss. Am J Otol. 1993 Mar; 14(2):183-5. PMID: 8503494.
        View in: PubMed
      271. Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl. 1993; 17F:188-91. PMID: 8412192.
        View in: PubMed
      272. Johnson CS, Chang MJ, Yu WD, Modzelewski RA, Grandis JR, Vlock DR, Furmanski P. Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemother Pharmacol. 1993; 32(5):339-46. PMID: 8339383.
        View in: PubMed
      273. Snyderman CH, Grandis JR, Johnson JT. Head and neck cancer. Arch Otolaryngol Head Neck Surg. 1993 Jan; 119(1):121. PMID: 8417737.
        View in: PubMed
      274. Grandis JR, Snyderman CH, Johnson JT, Yu VL, D'Amico F. Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer. Cancer. 1992 Oct 15; 70(8):2166-70. PMID: 1394047.
        View in: PubMed
      275. Grandis JR, Tweardy DJ. The role of peptide growth factors in head and neck carcinoma. Otolaryngol Clin North Am. 1992 Oct; 25(5):1105-15. PMID: 1408194.
        View in: PubMed
      276. Grandis JR, Johnson JT, Vickers RM, Yu VL, Wagener MM, Wagner RL, Kachman KA. The efficacy of perioperative antibiotic therapy on recovery following tonsillectomy in adults: randomized double-blind placebo-controlled trial. Otolaryngol Head Neck Surg. 1992 Feb; 106(2):137-42. PMID: 1738544.
        View in: PubMed
      277. Rubin J, Johnson JT, Myers EN. Stomal recurrence after laryngectomy: interrelated risk factor study. Otolaryngol Head Neck Surg. 1990 Nov; 103(5 ( Pt 1)):805-12. PMID: 2126104.
        View in: PubMed
      278. Rubin J, Johnson JT, Killeen R, Barnes L. Extramedullary plasmacytoma of the thyroid associated with a serum monoclonal gammopathy. Arch Otolaryngol Head Neck Surg. 1990 Jul; 116(7):855-9. PMID: 2363927.
        View in: PubMed
      279. Rubin J, Yu VL, Kamerer DB, Wagener M. Aural irrigation with water: a potential pathogenic mechanism for inducing malignant external otitis? Ann Otol Rhinol Laryngol. 1990 Feb; 99(2 Pt 1):117-9. PMID: 2301865.
        View in: PubMed
      280. Rubin J, Curtin HD, Yu VL, Kamerer DB. Malignant external otitis: utility of CT in diagnosis and follow-up. Radiology. 1990 Feb; 174(2):391-4. PMID: 2104989.
        View in: PubMed
      281. Rubin J, Stoehr G, Yu VL, Muder RR, Matador A, Kamerer DB. Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. Arch Otolaryngol Head Neck Surg. 1989 Sep; 115(9):1063-9. PMID: 2504254.
        View in: PubMed
      282. Rubin J, Yu VL, Stool SE. Malignant external otitis in children. J Pediatr. 1988 Dec; 113(6):965-70. PMID: 3142986.
        View in: PubMed
      283. Rubin J, Johnson JT, Wagner RL, Yu VL. Bacteriologic analysis of wound infection following major head and neck surgery. Arch Otolaryngol Head Neck Surg. 1988 Sep; 114(9):969-72. PMID: 3408577.
        View in: PubMed
      284. Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med. 1988 Sep; 85(3):391-8. PMID: 3046354.
        View in: PubMed
      Jennifer's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP